Ianalumab Produces Encouraging Early Activity in Phase 1 Study of CLL
Kerry Rogers, MD, discusses the findings observed in the phase 1b study of ianalumab in combination with ibrutinib as treatment of patients with chronic lymphocytic leukemia on ibrutinib therapy.
Kerry Rogers, MD, hematologist/oncologist, assistant professor, Department of Hematology, The Ohio State University Comprehensive Cancer Center–James, discusses the findings observed in the phase 1b study of ianalumab (VAY736) in combination with ibrutinib (Imbruvica) as treatment of patients with chronic lymphocytic leukemia (CLL) on ibrutinib therapy.
This therapy was tolerable, which was not surprising as antibodies are generally tolerable, Rogers says. One surprising finding, however, was the number of patients that had elimination of their CLL and were able to stop treatment. Despite this being a phase 1 study, many patients were able to achieve this, according to Rogers. The study was not powered to detect this, but it was great to see that level of efficacy early on, Rogers says.
